A Phase 1 interventional study of ODM-108 Part I and Placebo Part I in Healthy, sponsored by Orion Corporation, Orion Pharma. Terminated at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-02.
Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to investigate to what extent this new study drug is tolerated in humans.
The study is divided into 3 parts (Part III is optional and may go ahead depending on the results of Parts I and II). The volunteers will only be enrolled to one part of the study. In parts I and II the volunteer will receive active study drug or placebo. In part I the volunteers will receive a single dose of one of the eight planned escalating dose levels.
In part II volunteers will receive 4 planned dose levels based on the results obtained in Part 1 of the study, with the option to include an additional dosing group.
In optional part III the volunteer will receive ODM-108 and an already registered drug so that interactions with other drugs can be studied.
It will be investigated how quickly and to what extent the study drug is absorbed and eliminated from the body (this is called pharmacokinetics). In addition, in parts I and II the effect of the compound on the sensation of pain and on cognition (activities of thinking, understanding, learning, and remembering) will be investigated (this is called pharmacodynamics).
This is the first time that this compound is being given to humans.
The study will only take place after it has been approved by the Independent Ethics Committee.
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional exclusion criteria for Part I and II:
Additional exclusion criterion for Part II:
The following additional exclusion criterion will be checked in Part I and II:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral capsules dosage 0.2 - 240 mg once daily for one day
Drug: ODM-108 Part I
Oral capsules given once daily for one day
Drug: Placebo Part I
Oral capsules 4 dose levels to be decided after Part 1 of the study. 1 - 4 times a day for 7 days
Drug: ODM-108-Part II
Oral capsules 1 - 4 times per day for 7 days
Drug: Placebo Part II
Oral capsules 1-4 times daily for 7 to 10 days
Drug: ODM-108 Part III
Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
Drug: Midazolam
Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
Oral capsules 1 - 4 times daily for 7 to 10 days
Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
Number of participants with adverse events in Part I and Part II.
Clinically relevant changes from baseline of safety assessment
Time frame: From screening up to 8 weeks
Part III (optional) Effect of ODM-108 on the activity of CYP3A4 (cytochrome P450 3A4) isoenzymes
Measurement of biomarkers
Time frame: Day 1 up to Day 11
Part I Peak plasma concentration Cmax of ODM-108
Cmax of ODM-108 after single dosing
Time frame: Pre dose,15, 30, 45 mins, 1 h, 1 h 15, 1 h 30, 2 h, 2 h 30, 3 h, 4 h, 6 h, 8 h, 12h, 24 h, 48 h, 72 h, 96 h post dose at each dose level.
Part I Metabolite screening in plasma and urine
Metabolite screening in plasma and urine after single dosing
Time frame: Pre-dose and 30 min, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h and 48 h post dose at each dose level. Urine samples pre-dose and for 24 hours post dose at each dose level.
Part I Sedation scores on Visual Analogue Scales
Assessment of sedation by subject
Time frame: Pre-dose, 2 h 30 min and 10 h post dose at each dose level
Part I Cognitive function - Digital Symbol Substitution Test
Assessment of cognitive function
Time frame: Pre-dose, 2 h 30 min and 10 h post dose at each dose level
Part I Intensity of spontaneous pain
Intensity of spontaneous pain as assessed by a visual analogue scale
Time frame: Screening and day 1 at 1, 5, 15, 30, 60 and 120 min after capsaicin injection.
Part I Area of hyperalgesia
Area of hyperalgesia quantified by a Von Frey monofilament
Time frame: Screening and day 1 at 15, 30, 60 and 120 min after capsaicin injection.
Part I area of flare response
Area of flare response measured by Doppler blood flow scan
Time frame: Screening and day 1 at baseline and 15, 30, 60 and 120 min after capsaicin injection.
Part II Peak plasma concentration Cmax of ODM-108
Cmax of ODM-108 after multiple dosing
Time frame: Days 1 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose
Part II Peak plasma concentration Cmax of ODM-108 fed day 5 period 1
Cmax of ODM-108 after multiple dosing
Time frame: Days 1,5 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose
Part II Time to peak plasma concentration (tmax) of ODM-108
tmax of ODM-108 after multiple dosing
Time frame: Days 1 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose
Part II Time to peak plasma concentration (tmax) of ODM-108 fed day 5 period 1
tmax of ODM-108 after multiple dosing
Time frame: Days 1,5 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose
Part II Area under the plasma concentration versus time curve (AUC) of ODM-108.
AUC of ODM-108 after multiple dosing
Time frame: Days 1 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose
Part II Area under the plasma concentration versus time curve (AUC) of ODM-108 fed day 5 period 1
AUC of ODM-108 after multiple dosing
Time frame: Days 1,5 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose
Part II Elimination half-life of ODM-108
Elimination half-life of ODM-108 after multiple dosing
Time frame: Days 1 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose
Part II Elimination half-life of ODM-108- fed day 5 period 1
Elimination half-life of ODM-108 after multiple dosing
Time frame: Days 1,5 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose
Part II Binding of ODM-108 to proteins in plasma
Assessment of binding of ODM-108 to proteins in plasma
Time frame: Days 1 and 7 -1 h 30 min post dose
Part II Metabolite screening in plasma and urine
Metabolite screening in plasma and urine
Time frame: Day 1 and 7 pre-dose and 30 min, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h and 48 h post dose. Urine samples pre-dose and for 24 hours post dose at each dose level on days 1 and 7.
Part II Sedation scores on Visual Analogue Scales
Assessment of sedation by subject
Time frame: Day 1 and day 6 pre-dose, 2 h 30 min, and 10 h post dose
Part II Computerised psychomotor test battery measuring: attention, concentration, vigilance, memory, visual motor coordination and body sway.
Assessment of psychomotor function
Time frame: Days 1 and 6: pre-dose, approx. 2 h 30 min and 10 h after first daily ODM-108 dose
Part II Intensity of spontaneous pain
Assessed by numerical rating scale
Time frame: Screening and day 5 at 1, 5, 15, 30, 60 and 120 min after capsaicin injection.
Part II Area of hyperalgesia
Area of hyperalgesia quantified by a Von Frey monofilament
Time frame: Screening and day 5 at 5, 15, 30, 60 and 120 min after capsaicin injection.
Part II Cutaneous blood flow and area of flare response
Pain assessments
Time frame: Screening and day 5 pre -dose and 5, 15, 30, 60 and 120 min after capsaicin injection.
Part II Intensity of spontaneous pain
Intensity of spontaneous pain as assessed by a visual analogue scale
Time frame: Screening and day 7 at 1, 5, 15, 30, 60 and 120 min after mustard oil challenge.
Part II Area of hyperalgesia
Area of hyperalgesia quantified by a Von Frey monofilament
Time frame: Screening and day 7 at 5, 15, 30, 60 and 120 min after mustard oil challenge.
Part II Area of flare response
Area of flare response measured by Doppler blood flow scan
Time frame: Screening and day 7 baseline and 5, 15, 30, 60 and 120 min after mustard oil challenge.
Part III (optional) Peak plasma concentration Cmax of midazolam
Cmax of midazolam
Time frame: day 1 and day 10 or 13
Part III (optional) Time to peak plasma concentration (tmax) of midazolam
tmax of midazolam
Time frame: day 1 and day 10 or 13
Part III (optional) Area under the plasma concentration versus time curve (AUC) of midazolam.
AUC of midazolam
Time frame: day 1 and day 10 or 13 (
Part III (optional) ODM-108 levels in cerebrospinal fluid
Assessment of levels of ODM 108 in cerebrospinal fluid
Time frame: day 9
Part I Time to peak plasma concentration (tmax) of ODM-108
tmax of ODM-108 after single dosing
Time frame: Pre dose,15, 30, 45 mins, 1 h, 1 h 15,1 h 30, 2 h, 2 h 30, 3 h, 4 h, 6 h, 8 h, 12h, 24 h, 48 h, 72 h, 96 h post dose at each dose level.
Part I Area under the plasma concentration versus time curve (AUC) of ODM-108.
AUC of ODM-108 after single dosing
Time frame: Pre dose,15, 30, 45 mins, 1 h, 1 h 15,1 h 30, 2 h, 2 h 30, 3 h, 4 h, 6 h, 8 h, 12h, 24 h, 48 h, 72 h, 96 h post dose at each dose level.
Part I Elimination half-life of ODM-108
Elimination half-life of ODM-108 after single dosing
Time frame: Pre dose,15, 30, 45 mins, 1 h, 1 h 15,1 h 30, 2 h, 2 h 30, 3 h, 4 h, 6 h, 8 h, 12h, 24 h, 48 h, 72 h, 96 h post dose at each dose level.
Ran from Apr 2015 to primary completion in Apr 2016, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orion Corporation, Orion Pharma →